The 2022 edition arrived during a transition period for neonatal medicine. By 2022, hospitals had stabilized from initial COVID-19 surges, but supply chain issues for generic drugs were rampant. The reflected these real-world constraints by adding expanded notes on alternative formulations and therapeutic substitutions.
| Feature | NeoFax 2022 PDF | NeoFax 2025 (Current) | | :--- | :--- | :--- | | | Palivizumab based on old AAP guidelines | Updated nirsevimab (Beyfortus) dosing | | COVID-19 Therapies | Limited data | Full remdesivir neonatal protocol | | Supply shortage notes | Historical (2022 shortages) | Dynamic real-time shortages | | IV compatibility | Static tables from 2021 data | Updated with new drugs (e.g., levetiracetam) | neofax 2022 pdf
Detailed information on infant formulas and human milk fortifiers to assist in parenteral and enteral nutrition planning. The 2022 edition arrived during a transition period
Key updates in the 2022 edition include: | Feature | NeoFax 2022 PDF | NeoFax
To understand the demand for the 2022 PDF, one must first appreciate the authority of the text itself. Originally developed by physicians at the University of Virginia and later expanded by Dr. John E. Van Den Anker and colleagues, NeoFax (formerly Neofax ) has served as the "pocket bible" for neonatal pharmacology since the late 1970s.
Without a resource like NeoFax , clinicians would be forced to extrapolate from adult data, a practice fraught with danger. The NeoFax 2022 PDF represents the latest accumulation of decades of research, refining these protocols to their most current standard.